頭孢哌酮舒巴坦鈉治療淋病臨床評價

李寧 李莉

【摘要】目的：探討對淋病患者采用頭孢哌酮舒巴坦鈉治療的臨床療效。方法：選取我院皮膚性病科2010年1月至2015年1月收治的淋病患者104例作為研究對象，回顧性分析其臨床資料。按照治療藥物將所有患者劃分為對照組和觀察組各52例，其中對照組治療藥物為加替沙星聯合阿奇霉素，觀察組治療藥物為頭孢哌酮舒巴坦鈉，對比兩組臨床療效及不良反應發生率。結果： 對照組臨床療效為75.0%，明顯低于觀察組94.2%，對比差異明顯（P<0.05）；對照組病原菌轉陰率為80.8%，明顯低于觀察組100.0%，對比差異明顯（P<0.05）；對照組不良反應發生率為25.0%，明顯高于觀察組5.8%，對比差異明顯（P<0.05）；對照組復發率為23.1%，明顯高于觀察組5.8%，對比差異明顯（P<0.05）。結論： 頭孢哌酮舒巴坦鈉治療淋病臨床療效明顯，安全性高，可減少復發，值得推廣。

【關鍵詞】：頭孢哌酮舒巴坦鈉；加替沙星；阿奇霉素；淋病

【Abstract】Objectives： To investigate the curative effect of cefoperazone sulbactam sodium for gonorrhea patients. Methods： 104 gonorrhea patients in our hospital between January 2010 and January 2015 were selected as research objects， and their clinical data was retrospectively analyzed. According to drugs received， all patients were divided into control group and observation group， 52 cases in each group. The control group received joint treatment of gatifloxacin and azithromycin， while observation group received cefoperazone sulbactam sodium. The clinical curative effect and the incidence of adverse reactions were compared. Results： The clinical curative effect of control group was 75.0%， significantly lower than the observation group of 94.2%， with significant difference （P< 0.05）. The negative conversion ratio of control group was 80.8%， significantly lower than the observation group of 100.0%， with significant difference （P< 0.05）. The incidence of adverse reactions in control group was 25.0%， significantly higher than the observation group of 5.8%， with significant difference （P< 0.05）. The recurrence rate in control group was 23.1%， significantly higher than the observation group of 5.8%， with significant difference （P< 0.05）. Conclusion： Cefoperazone sulbactam sodium has remarkable curative effect for gonorrhea， with high safety and low recurrence， which is worth promoting.

【Key words】Cefoperazone sulbactam sodium； Gatifloxacin； Azithromycin； Gonorrhea

【中圖分類號】R759.2【文獻標志碼】A

淋病為臨床性傳播疾病之一，主要感染因素為淋病奈瑟球菌，可與解脲支原體感染與沙眼衣原體出現合并感染。據調查[1]，淋病奈瑟球菌、解脲支原體以及沙眼衣原體在可疑人群中的感染率分別為8.8%、32.1%以及19.8%，致使男女泌尿生殖系統出現膿性感染。經研究后報道，分析院內淋病感染病原耐藥性后得知淋病奈瑟菌耐青霉素菌株不斷增加，治療淋病的首選藥物為頭孢三嗪，然而其費用高昂，在基層醫院以及欠發達地區無法推廣應用。氟喹諾酮類藥物以往為常用藥物，然而臨床已經發現耐喹諾酮淋球菌，符合美國不推薦應用該類藥物治療淋病的決定。頭孢哌酮舒巴坦鈉為頭孢哌酮與舒巴坦鈉的合成藥，逐漸被臨床用于治療淋病。本文為詳細探討頭孢哌酮舒巴坦鈉治療淋病的臨床療效，現選取我院皮膚性病科收治的淋病患者104例作為研究對象，將詳細情況報告如下?！?br>